Ultragenyx Pharma (RARE) PT Raised to $136 at Canaccord Genuity

Canaccord Genuity analyst Whitney Ijem raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $136.00 (from $121.00) while maintaining a Buy rating.

The analyst commented: "RARE delivered a top- and bottom-line beat for 4Q24 driven by continued growth and demand in the Crysvita, Dojolvi, and Evkeeza franchises. With three potential commercial launches - UX111 for MPSIIIA (BLA already filed; PDUFA decision and launch expected 2H25), DTX401 for GSD1a (BLA filing expected mid-2025), and setrusumab for OI (Ph3 data readout either mid-year or by YE) - in the next ~year and expected full year GAAP profitability in 2027, we continue to believe shares are meaningfully undervalued. Reiterate BUY."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating